Liposomal Vaccine or Adjuvant Products
Product Details Publish Data FAQs Resources
Product Details
For years, Creative Biolabs has been the frontrunner in the field of liposomes. Based on our extensive expertise in vaccines, we can provide you with diverse and effective vaccine delivery solutions. Whether you need efficient encapsulation, targeted delivery, or enhanced stability for your vaccines, we have the knowledge and resources to meet your needs.
Based on the nature of liposomes, we can provide you with liposome-based vaccine products to solve the obstacles you face in the research and development process and accelerate your research in the field of vaccines. Through transporting antigens, adjuvants, or functional molecules by phospholipid and cholesterol encapsulation or adsorption, liposomes can amplify immune effects and direct immune responses towards either Th1 or Th2 pathways. Liposomes can also bind to functional molecules such as toll-like receptor agonists/ligands or environmental stimulus-sensitive molecules for sustained or signal-stimulated release. In addition, it is possible to reduce the frequency of vaccine administration by using sustained-releasing liposomes, which contribute to achieving the delivery of multifunctional vaccines.
Experience unparalleled efficacy in vaccine delivery with our specialized solutions. By enhancing the interaction between your vaccine and the antigen presentation cell (APC), we can provide you with highly effective anti-pathogen immunity that excels in scale, quality, breadth, and persistence. Don't miss out on the opportunity to have innovative and efficient vaccine delivery. Contact us now and discover the limitless potential of our cutting-edge solutions.
Publish Data
Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis
Author: Lage, D. P., Ribeiro, P. A., et al.
The study explores the potential of a ChimeraT/liposome formulation as a candidate vaccine for human visceral leishmaniasis (VL). ChimeraT, a synthetic recombinant vaccine, contains T-cell epitopes from Leishmania proteins. The research highlights the immunogenicity and efficacy of ChimeraT when incorporated into liposomes, which are biodegradable, non-toxic, and capable of inducing a Th1-type immune response.
In experiments, BALB/c mice immunized with ChimeraT/liposome showed significantly higher levels of IFN-γ, IL-12, and GM-CSF compared to controls, indicating a strong Th1 response. This formulation also led to a significant reduction in parasite load in mouse organs post-infection. The ChimeraT/liposome group exhibited a notable decrease in L. infantum burden, with an over 99.5% reduction in parasite numbers. Furthermore, post-therapy serological analysis in VL patients revealed increased IgG2/IgG1 ratios after treatment, suggesting a shift towards a protective immune response. The study demonstrates that the ChimeraT/liposome vaccine induces a potent and protective Th1-type response, making it a promising candidate for further development and potential human trials.
Fig.1 Evaluation of the parasite burden by RT-PCR.1,2
FAQs
What are the benefits of using liposomes as vaccine adjuvants?
Liposomes are advantageous as vaccine adjuvants due to their biocompatibility, ability to enhance immune responses, and versatility in delivering both hydrophilic and hydrophobic antigens. They can also be tailored to elicit specific immune responses, enhancing the efficacy of vaccines.
What factors influence the performance of liposomal vaccines?
The performance of liposomal vaccines is influenced by factors such as liposome size, lamellarity, surface charge, and lipid composition. These parameters affect the stability, biodistribution, and immunogenicity of the vaccine, making them crucial for optimizing vaccine formulations.
What are the common methods for preparing liposomal vaccines?
Liposomal vaccines are typically prepared using methods such as thin-film hydration, reverse-phase evaporation, and microfluidics. These techniques ensure the proper encapsulation of antigens and adjuvants, maintaining the stability and efficacy of the vaccine.
What types of immune responses can liposomal adjuvants induce?
Liposomal adjuvants can be designed to induce various types of immune responses, including Th1, Th2, and Th17 responses. This is achieved by modifying the liposome's physicochemical properties and incorporating specific immunostimulatory agents, thereby tailoring the immune response to the desired outcome.
What challenges are associated with liposomal vaccine development?
Key challenges in liposomal vaccine development include ensuring stability, scalability, and reproducibility of the formulations. Overcoming these challenges requires precise control over the preparation methods, thorough characterization of the liposomes, and rigorous stability testing under different conditions.
Resources
References
-
Lage, Daniela P., et al. "Liposomal formulation of ChimeraT, a multiple T-cell epitope-containing recombinant protein, is a candidate vaccine for human visceral leishmaniasis." Vaccines 8.2 (2020): 289.
-
under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not For Clinical Use
